Literature DB >> 20714918

In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.

Giorgio Zauli1, Federica Corallini, Sonia Zorzet, Vittorio Grill, Roberto Marzari, Paola Secchiero.   

Abstract

A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10 mg/kg) were able to significantly increase the median survival time of lymphoma-bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20714918     DOI： 10.1007/s10637-010-9519-y

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  8 in total

Review 1.  Engineered antibody fragments and the rise of single domains.

Authors:  Philipp Holliger; Peter J Hudson
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

2.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.

Authors:  S K Kelley; L A Harris; D Xie; L Deforge; K Totpal; J Bussiere; J A Fox
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

Review 3.  Development trends for monoclonal antibody cancer therapeutics.

Authors:  Janice M Reichert; Viia E Valge-Archer
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

Review 4.  Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

Authors:  Roberta Di Pietro; Giorgio Zauli
Journal:  J Cell Physiol       Date:  2004-12       Impact factor: 6.384

Review 5.  Role of full-length osteoprotegerin in tumor cell biology.

Authors:  G Zauli; E Melloni; S Capitani; P Secchiero
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 6.  Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.

Authors:  Paola Secchiero; Giorgio Zauli
Journal:  Curr Opin Hematol       Date:  2008-01       Impact factor: 3.284

Review 7.  Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

Authors:  Avi Ashkenazi; Pamela Holland; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

8.  Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.

Authors:  P Secchiero; D Sblattero; C Chiaruttini; E Melloni; P Macor; S Zorzet; C Tripodo; F Tedesco; R Marzari; G Zauli
Journal:  Int J Immunopathol Pharmacol       Date:  2009 Jan-Mar       Impact factor: 3.219
  8 in total
  2 in total

Review 1.  CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

Authors:  Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

2.  The Strategy of Conditionally Replicating Adenovirus-Mediated PreS2 Mini-Antibody Expression Has Dual Effects of Inhibiting HBV Infection and Preventing Hepatocellular Carcinoma.

Authors:  Ziheng Ye; Su Zeng; Peipei Xu; Wenfei Liu; Shoufei Wang; Xiaotian Xia; Changqing Su; Minggao Guo
Journal:  Cancer Manag Res       Date:  2021-02-24       Impact factor: 3.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.